Exon skipping of FcεRIß eliminates expression of the high-affinity IgE receptor in mast cells with therapeutic potential for allergy.
Proc Natl Acad Sci U S A
; 113(49): 14115-14120, 2016 12 06.
Article
em En
| MEDLINE
| ID: mdl-27872312
ABSTRACT
Allergic diseases are driven by activation of mast cells and release of mediators in response to IgE-directed antigens. However, there are no drugs currently available that can specifically down-regulate mast cell function in vivo when chronically administered. Here, we describe an innovative approach for targeting mast cells in vitro and in vivo using antisense oligonucleotide-mediated exon skipping of the ß-subunit of the high-affinity IgE receptor (FcεRIß) to eliminate surface high-affinity IgE receptor (FcεRI) expression and function, rendering mast cells unresponsive to IgE-mediated activation. As FcεRIß expression is restricted to mast cells and basophils, this approach would selectively target these cell types. Given the success of exon skipping in clinical trials to treat genetic diseases such as Duchenne muscular dystrophy, we propose that exon skipping of FcεRIß is a potential approach for mast cell-specific treatment of allergic diseases.
Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Degranulação Celular
/
Splicing de RNA
/
Oligonucleotídeos Antissenso
/
Receptores de IgE
/
Dermatite Alérgica de Contato
/
Mastócitos
Tipo de estudo:
Evaluation_studies
/
Prognostic_studies
Limite:
Animals
/
Female
/
Humans
Idioma:
En
Ano de publicação:
2016
Tipo de documento:
Article